Back to Search Start Over

How should we manage bevacizumab toxicity in lung cancer patients?

Authors :
Pascaline Boudou-Rouquette
Daniel Dusser
Jérôme Alexandre
Olivier Huillard
Cécile Defaucheux
François Goldwasser
Jeanne Chapron
Source :
Lung Cancer Management. 3:355-363
Publication Year :
2014
Publisher :
Future Medicine Ltd, 2014.

Abstract

SUMMARY Bevacizumab is an antiangiogenic targeted therapy approved for the treatment of patients with advanced non-small-cell lung cancer other than predominantly squamous cell histology in addition to platinum-based chemotherapy. The safety of bevacizumab has been assessed in studies across most cancer types and bevacizumab is generally well tolerated. Some specific issues associated with the use of bevacizumab in lung cancer are discussed in this report (pulmonary hemorrhage, brain metastases or concurrent thoracic radiotherapy) as well as frequent and clinically relevant adverse events and their management. Oncologists and pulmonologists should be aware of such events and their management since the prescription of bevacizumab concerns many patients and the future use in maintenance therapy will be associated with prolonged treatment.

Details

ISSN :
17581974 and 17581966
Volume :
3
Database :
OpenAIRE
Journal :
Lung Cancer Management
Accession number :
edsair.doi...........424328d458769eba0c6daa32f0723901
Full Text :
https://doi.org/10.2217/lmt.14.25